Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF +0.24%80 Cash-to-Debt is 0.14 as of Jun. 2026, which is 26% below its 10-year median of 0.19. GuruFocus rates ERFSF with a GF Score™ of 80/100 and a GF Value™ of $75.73 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 83.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Eurofins Scientific SE's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.14.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Eurofins Scientific SEcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Eurofins Scientific SE's Cash-to-Debt or its related term are showing as below:
ERFSF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.19 Max: 0.6
Current: 0.14
During the past 13 years, Eurofins Scientific SE's highest Cash to Debt Ratio was 0.60. The lowest was 0.08. And the median was 0.19.
ERFSF's Cash-to-Debt is ranked worse than 83.17% of 208
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.25
vs ERFSF: 0.14
Eurofins Scientific SE (OTCPK:ERFSF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Eurofins Scientific SE Cash-to-Debt Related Terms
Eurofins Scientific SE Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (ERFSF) has a Cash-to-Debt of 0.14 as of Jun. 2026. This is 26% below median its historical median of 0.19. Over the past decade, Eurofins Scientific SE's Cash-to-Debt has ranged from 0.08 to 0.60. According to the industry distribution chart, Eurofins Scientific SE ranks #173 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 83.2%.
Is Eurofins Scientific SE's Cash-to-Debt too high?
Eurofins Scientific SE's current Cash-to-Debt of 0.14 is 26% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.60. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.25. Eurofins Scientific SE's value of 0.14 is 88.8% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #173 out of 208 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #173 out of 208 companies for Cash-to-Debt. This places Eurofins Scientific SE in the lower half of its industry. The industry median Cash-to-Debt is 1.25. Eurofins Scientific SE's value of 0.14 is 88.8% below this benchmark. Historically, Eurofins Scientific SE's own Cash-to-Debt has ranged from 0.08 to 0.60 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.25, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.25, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Cash-to-Debt of 0.14 is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Cash-to-Debt is 0.14, which is 26% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Modestly Overvalued. The stock's GF Value™ is $75.73, compared to a current price of $86.61 — trading 14.4% above its estimated fair value. The current Cash-to-Debt is 0.14, which is 26% below median its 10-year median of 0.19 and 88.8% below the Medical Diagnostics & Research industry median of 1.25. Eurofins Scientific SE's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current Cash-to-Debt is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $86.61 is trading 14.4% above its estimated GF Value™ of $75.73.
GuruFocus considers Eurofins Scientific SE to be Modestly Overvalued.
Key valuation signals for ERFSF:
Cash-to-Debt: 0.14 (26% below median its 10-year median of 0.19)
GF Value™: $75.73 vs. price of $86.61 (14.4% above fair value)
Industry Position: 88.8% below the Medical Diagnostics & Research median (#173 of 208)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
80GF Score
Get the complete analysis for ERFSF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
